Business
CareDx to Report Fourth Quarter and Full Year 2021 Financial Results
SOUTH SAN FRANCISCO, Calif., Feb. 17, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development,
About this update from Caredx, Inc.
[{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., Feb. 17, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients – today announced it will report financial results for the fourth quarter and full year 2021 after market close on Thursday, February 24, 2022. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Individuals interested in listening to the conference call may do so by dialing 855-327-6837 for domestic callers or 631-891-4304 for international callers. Please reference Conference ID: 1001789. To listen to a live webcast, please visit the investor relations section of CareDx’s website at: investors.caredxinc.com. About CareDx – The Transplant CompanyCareDx, Inc., headquartered in South San Francisco, California, is a leading precision medicine solutions company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.CareDx.com. CONTACTS:CareDx, Inc.Investor RelationsIan Cooney415-287-2300 x [email protected] \nSource: CareDx, Inc.","length":3492,"tagName":"div"}]